The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff

Research output: Contribution to journalArticleResearchpeer-review

132 Citations (Scopus)

Abstract

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

Original languageEnglish
Article number104787
Number of pages4
JournalAntiviral Research
Volume178
DOIs
Publication statusPublished - Jun 2020

Cite this